Evidence map›Paper›PMID 39283290›Full record

ArticleFuture oncology (London, England)2024

Safety and efficacy of itacitinib, a selective JAK1 inhibitor, in advanced hepatocellular cancer: Phase 1b trial (JAKAL).

Alessandro Troiani, Maria Martinez, Caroline Ward, Charlotte Wilhelm Benartzi, David J Pinato, Rohini Sharma

Registry-linked trialAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in Future oncology (London, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04358185 (A Phase Ib Study of Itacitinib, a JAK1 Inhibitor, in Advanced Hepatocellular Carcinoma), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04358185 phase1completednot on this map

A Phase Ib Study of Itacitinib, a JAK1 Inhibitor, in Advanced Hepatocellular Carcinoma

TypeinterventionalSponsorImperial College LondonRan2018 to 2023Enrolled19ConditionsAdvanced Hepatocellular CarcinomaArmsItacitinib
3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Alessandro TroianiDivision of Surgery & Cancer, Imperial College London, Hammersmith Hospital, Du Cane Road, W12 0NN, London, UK.ORCID 0009-0008-8946-9492
Maria MartinezDivision of Surgery & Cancer, Imperial College London, Hammersmith Hospital, Du Cane Road, W12 0NN, London, UK.
Caroline WardDivision of Surgery & Cancer, Imperial College London, Hammersmith Hospital, Du Cane Road, W12 0NN, London, UK.
Charlotte Wilhelm BenartziUniversity Hospital of Wales, Heath Park, Cardiff.ORCID 0000-0003-4927-6158
David J PinatoDivision of Surgery & Cancer, Imperial College London, Hammersmith Hospital, Du Cane Road, W12 0NN, London, UK.ORCID 0000-0002-3529-0103
Rohini SharmaDivision of Surgery & Cancer, Imperial College London, Hammersmith Hospital, Du Cane Road, W12 0NN, London, UK.

Funding

Imperial College LondonIncyte
6 · The paper itself

Abstract

Overactivation of the JAK/STAT pathway is one of the drivers for the pathophysiology of hepatocellular carcinoma (HCC). We propose a Phase Ib study to evaluate the safety and efficacy of itacitinib, a selective JAK1 inhibitor, as a second-line treatment for patients with advanced or metastatic HCC.Twenty-five patients will receive 400 mg itacitinib orally daily, 28-day cycle. Safety will be reviewed prior to each cycle. Tumor response assessed every 2 months until disease progression, death or withdrawal. Tumor biopsies and blood samples will be taken for presence of

Indexed as

Carcinoma, HepatocellularClinical Trials, Phase I as TopicJanus Kinase 1Liver NeoplasmsProtein Kinase InhibitorsAcetonitrilesAdultAgedFemaleHumansMaleMiddle AgedNeoplasm StagingPiperidinesPyrazolesPyrimidinesAcetonitrilesitacitinibJAK1 protein, humanJanus Kinase 1PiperidinesProtein Kinase InhibitorsPyrazolesPyrimidinesPyrrolesefficacyhepatocellular cancerINCB039110itacitinibJAK/STATliver cirrhosisPhase Isafety

Identifiers

PMID39283290
PMCPMC11572186

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.